🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 11 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 12/06/2019 | 172,60 | 173,47 | 169,26 | 170,63 | -0,80% | 2,44% | 1.444.600 |
| 11/06/2019 | 174,08 | 174,88 | 171,75 | 172,00 | -0,49% | 1,80% | 1.442.300 |
| 10/06/2019 | 173,29 | 174,12 | 171,51 | 172,84 | -0,39% | 1,51% | 1.025.100 |
| 07/06/2019 | 169,43 | 173,98 | 169,26 | 173,51 | +3,43% | 2,79% | 1.109.600 |
| 06/06/2019 | 173,22 | 173,99 | 167,42 | 167,75 | -3,19% | 3,79% | 1.261.100 |
| 05/06/2019 | 171,90 | 174,00 | 170,39 | 173,27 | +1,17% | 2,10% | 1.254.500 |
| 04/06/2019 | 168,16 | 172,97 | 167,08 | 171,27 | +2,78% | 3,50% | 1.456.800 |
| 03/06/2019 | 166,87 | 168,85 | 165,80 | 166,64 | +0,28% | 1,83% | 1.080.600 |
| 31/05/2019 | 168,49 | 169,99 | 166,10 | 166,18 | -2,40% | 2,31% | 982.500 |
| 30/05/2019 | 167,26 | 170,50 | 167,26 | 170,26 | +2,23% | 1,94% | 902.900 |
| 29/05/2019 | 171,15 | 171,87 | 166,30 | 166,55 | -3,59% | 3,25% | 1.788.400 |
| 28/05/2019 | 172,24 | 173,79 | 171,06 | 172,76 | +0,58% | 1,58% | 1.542.100 |
| 24/05/2019 | 174,31 | 175,94 | 171,37 | 171,77 | -0,72% | 2,62% | 1.115.700 |
| 23/05/2019 | 171,61 | 173,32 | 169,50 | 173,01 | +0,37% | 2,23% | 1.272.800 |
| 22/05/2019 | 168,47 | 174,29 | 168,47 | 172,37 | +1,92% | 3,45% | 1.230.400 |
| 21/05/2019 | 167,89 | 170,15 | 167,38 | 169,12 | +2,05% | 1,65% | 703.300 |
| 20/05/2019 | 167,77 | 168,25 | 165,68 | 165,73 | -1,78% | 1,53% | 644.300 |
| 17/05/2019 | 168,90 | 170,84 | 167,97 | 168,73 | -0,88% | 1,70% | 898.200 |
| 16/05/2019 | 167,63 | 173,41 | 167,63 | 170,23 | +2,01% | 3,45% | 1.688.900 |
| 15/05/2019 | 165,41 | 168,22 | 164,96 | 166,88 | +0,10% | 1,97% | 663.700 |
| 14/05/2019 | 165,60 | 167,58 | 164,96 | 166,72 | +1,28% | 1,58% | 938.200 |
| 13/05/2019 | 165,70 | 167,48 | 164,07 | 164,61 | -2,51% | 2,06% | 1.118.500 |
| 10/05/2019 | 169,36 | 169,36 | 164,31 | 168,85 | -0,62% | 2,98% | 805.700 |
| 09/05/2019 | 167,40 | 170,50 | 166,48 | 169,91 | +0,53% | 2,40% | 820.200 |
| 08/05/2019 | 170,06 | 171,54 | 168,40 | 169,01 | -0,75% | 1,85% | 1.121.600 |
| 07/05/2019 | 172,33 | 174,38 | 168,59 | 170,28 | -2,56% | 3,36% | 1.345.900 |
| 06/05/2019 | 170,30 | 175,15 | 169,95 | 174,76 | +0,51% | 3,05% | 888.300 |
| 03/05/2019 | 170,05 | 174,19 | 169,46 | 173,87 | +2,55% | 2,78% | 971.800 |
| 02/05/2019 | 172,10 | 172,49 | 167,80 | 169,54 | -1,77% | 2,73% | 1.209.800 |
| 01/05/2019 | 168,76 | 175,60 | 168,51 | 172,60 | +2,14% | 4,20% | 1.824.800 |